Novartis AG (NVS) Shares are Up 2.33%

Novartis AG (NVS) : Traders are bullish on Novartis AG (NVS) as it has outperformed the S&P 500 by a margin of 1.46% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 1.7%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 2.33% in the last 1 week, and is up 8.31% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

Novartis AG (NYSE:NVS): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $83.46 and $83.18 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $83.58. The buying momentum continued till the end and the stock did not give up its gains. It closed at $83.51, notching a gain of 0.93% for the day. The total traded volume was 1,129,993 . The stock had closed at $82.74 on the previous day.


The stock has recorded a 20-day Moving Average of 2.61% and the 50-Day Moving Average is 5.06%. Novartis AG is up 9.19% in the last 3-month period. Year-to-Date the stock performance stands at 0.84%.

Novartis AG is a holding company that, through its subsidiaries, is engaged in development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals around the world. Its portfolio includes medicines, eye care, generic pharmaceuticals, preventive vaccines and over-the-counter (OTC) products. The Companys segments include Pharmaceuticals, which include patent-protected prescription medicines; Alcon, which include surgical, ophthalmic pharmaceutical and vision care products; Sandoz, which include generic pharmaceuticals, and Consumer Health, which includes the OTC Division. Pharmaceuticals products include Afinitor/Votubia, Exjade, Galvus, Exforge and Voltaren, among others. Its Sandoz products include Valsartan (Diovan), Cyclophosphamide injection and AirFluSal Forspiro, among others. Its OTC offers readily available consumer medicine. The Company operates Admune Therapeutics as a wholly owned subsidiary.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.